All Oncology News

NCCN Grants Category 2A Recommendation to Decitabine/Cedazuridine Combo for MDS

November 23rd 2020

November 23, 2020 - The National Comprehensive Cancer Work has updated its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes given the combination of decitabine and cedazuridine a category 2a recommendation for the treatment of adult patients with intermediate- and high-risk MDS.

JAK Inhibitors Continue to Shape Myelofibrosis Paradigm

November 23rd 2020

 John O. Mascarenhas, MD, discusses how the positioning of JAK inhibitors in myelofibrosis has shifted, and also pointed to new agents under investigation.

Role of HER2-Directed Therapies Rapidly Evolves in Esophageal and Gastric Cancer

November 23rd 2020

November 23, 2020 - Yelena Y. Janjigian, MD, discusses future research efforts are focused on examining anti–PD-1 combination strategies, particularly with HER2-directed therapies.

T-cell Signatures Suggest Existence of Immune-Responsive Microsatellite-Stable mCRPC

November 23rd 2020

November 23, 2020 - Patients with microsatellite instable metastatic castration-resistant prostate cancer have a distinct T-cell signature that is detectable in the peripheral blood.

Oxnard on Opening the Door for Precision Medicine in Lung Cancer

November 23rd 2020

In our exclusive interview, Dr. Oxnard explained how precision medicine has affected the treatment landscape of lung cancer, discussed the current capabilities of liquid biopsy, and forecasted the future of precision oncology in the field.

Standardized Frontline CDK4/6 Inhibition Sets the Stage for Further Research in HR+/HER2- Breast Cancer

November 23rd 2020

November 23, 2020 — Katherine K. Clifton, MD, discusses the utility of CDK4/6 inhibitors as frontline treatment for patients with HR-positive/HER2-negative breast cancer, the growing role of PI3K inhibitors in this space, and potential future research directions with these treatments.

Tebentafusp Improves OS in Frontline Metastatic Uveal Melanoma

November 23rd 2020

November 23, 2020 - Tebentafusp showed superiority in overall survival compared with investigator’s choice of therapy in patients with previously untreated metastatic uveal melanoma.

Denosumab Approved in China for Prevention of Skeletal-Related Events in Bone Metastases From Solid Tumors, Myeloma

November 23rd 2020

November 23, 2020 - The China National Medical Products Administration has approved denosumab for the prevention of skeletal-related events in patients with bone metastases from solid tumors and in those with multiple myeloma.

Ripretinib Shows Antitumor Activity in Fourth-Line KIT/PDGFRA-Mutated Advanced GIST

November 23rd 2020

November 23, 2020 - Ripretinib demonstrated clinically meaningful activity in patients with fourth-line or later advanced gastrointestinal stromal tumor and several, heterogeneous genetic subsets of KIT/PDGFRA mutations.

Next-Generation Endocrine Therapy Moves Forward in Breast Cancer Trial

November 23rd 2020

November 24, 2020 — Amcenestrant, a new oral form of endocrine therapy that has shown early signs of efficacy, is being evaluated against the current standards of care in patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer.

x